Renaissance Technologies LLC Trims Position in Delcath Systems, Inc. $DCTH

Key Points

• Renaissance Technologies cut its Delcath Systems stake by 57.1% in the first quarter, selling 206,299 shares and retaining 155,300 shares worth approximately $1.44 million. Institutional investors collectively own 61.12% of DCTH.
• Delcath reported quarterly revenue of $29.13 million and earnings of $0.07 per share, beating analyst estimates. Analysts expect the company to post a $0.17-per-share loss for the current fiscal year.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $23.17. However, shares near their 52-week high and the company’s expected near-term losses present valuation and execution risks.

Renaissance Technologies LLC decreased its holdings in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 57.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 155,300 shares of the company's stock after selling 206,299 shares during the period. Renaissance Technologies LLC owned approximately 0.45% of Delcath Systems worth $1,441,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Sei Investments Co. raised its stake in Delcath Systems by 100.0% during the 1st quarter. Sei Investments Co. now owns 44,058 shares of the company's stock valued at $409,000 after acquiring an additional 22,029 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Delcath Systems in the first quarter valued at approximately $306,000. XTX Topco Ltd increased its holdings in shares of Delcath Systems by 339.4% in the fourth quarter. XTX Topco Ltd now owns 71,193 shares of the company's stock valued at $719,000 after purchasing an additional 54,990 shares during the period. Millennium Management LLC raised its stake in shares of Delcath Systems by 3.0% during the fourth quarter. Millennium Management LLC now owns 246,444 shares of the company's stock worth $2,489,000 after purchasing an additional 7,190 shares during the last quarter. Finally, Man Group plc raised its stake in shares of Delcath Systems by 34.1% during the fourth quarter. Man Group plc now owns 38,158 shares of the company's stock worth $385,000 after purchasing an additional 9,705 shares during the last quarter. Institutional investors and hedge funds own 61.12% of the company's stock.

Delcath Systems Price Performance

Shares of DCTH stock opened at $17.11 on Thursday. The business's fifty day moving average price is $12.75 and its 200 day moving average price is $11.02. The firm has a market capitalization of $593.72 million, a PE ratio of 1,712.71 and a beta of 0.52. Delcath Systems, Inc. has a 1-year low of $8.12 and a 1-year high of $17.42.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.16. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%.The company had revenue of $29.13 million during the quarter, compared to the consensus estimate of $26.25 million. Equities research analysts expect that Delcath Systems, Inc. will post -0.17 earnings per share for the current fiscal year.

Delcath Systems News Summary

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Positive analyst revisions: HC Wainwright maintained a Buy rating and a $32 price target while sharply raising its EPS forecasts. The firm now expects DCTH to lose $0.17 per share in fiscal 2026, versus a prior estimate of a $0.88 loss, and projects a return to profitability in fiscal 2027. Longer-term estimates were also increased, including 2028 EPS of $0.56, 2029 EPS of $0.97 and 2030 EPS of $1.46. MarketBeat analyst estimates
• Positive Sentiment: Zacks upgraded DCTH: Zacks Research moved its rating from “Hold” to “Strong Buy,” citing improving earnings expectations and recent price strength. Zacks rating update
• Positive Sentiment: Momentum remains favorable: Zacks identified Delcath as a candidate for trend and momentum investors, indicating that the stock has outperformed enough to pass its recent-price-strength screens. Zacks trend investor article
• Neutral Sentiment: Short-interest data offers little signal: Reported short interest was zero shares, unchanged from the prior period, with a zero-day short ratio. The accompanying claim of a “significant increase” appears inconsistent with the figures, so it is unlikely to explain current trading.
• Negative Sentiment: Near-term valuation and technical risk: DCTH is trading close to its 52-week high after a substantial run-up. With the company still expected to post a loss in the near term, investors may be taking profits or waiting for additional execution before pushing the stock higher.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on DCTH shares. BTIG Research lifted their price objective on shares of Delcath Systems from $17.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Zacks Research upgraded shares of Delcath Systems from a "hold" rating to a "strong-buy" rating in a research note on Monday. Weiss Ratings restated a "sell (d+)" rating on shares of Delcath Systems in a research note on Friday, August 7th. Wall Street Zen raised shares of Delcath Systems from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $32.00 price target (up from $30.00) on shares of Delcath Systems in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $23.17.

Delcath Systems Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company's core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.

Want to see what other hedge funds are holding DCTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Delcath Systems, Inc. (NASDAQ:DCTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source